| Wissenschaftl. Titel | A phase II, open-label, non-randomized, multi-center study evaluating the efficacy and safety of nivolumab plus ipilimumab in patients with cancer of unknown primary site who are relapsed after or refractory to platinum-based chemotherapy (CheCUP) |
| Erkrankung |
CUP:
Cancer of unknown primary:
Alle Linien
|
| Kurzprotokoll | Kurzprotokoll |
| Links | Weiterführende Informationen (HD) Weiterführende Informationen (M) Weiterführende Informationen (NIH) Weiterführende Informationen (EudraCT) |
erstellt 15.03.2021 Data entry XI CCP
geändert 22.05.2023 Data entry III CCP